BeyondSpring vs NovaBridge Biosciences
BYSI and NBP side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BYSI and NBP compare
BeyondSpring scores higher on the StockData Score (4 against 0 for NovaBridge Biosciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BYSI | NBP |
|---|---|---|
| Size and price | ||
| Share price | $0.644 | $0.861 |
| Change, 1 year | −66.6% | −79.9% |
| Change, 5 years | −95.1% | −98.7% |
| Beta (5Y) | 0.54 | 1.49 |
| Employees | 44 | 220 |
| StockData Score | ||
| Total score | 4 (better) | 0 |
| Valuation score | 0 | 0 |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 4 (better) | 0 |
| Dividend score | 0 | 0 |
| Financial health | ||
| Current ratio | 0.70 | – |
| Piotroski F-score | 2 | – |
| Ownership | ||
| Held by institutions | 14.7% | 9.3% |
| Held by insiders | 31.2% | 33.3% |
| Insider net buying, 12 months | $0 | $423K (better) |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 8.0% | – |
Go deeper
- BYSI stock overview
- BYSI income statement
- BYSI valuation and score
- NBP stock overview
- NBP income statement
- NBP valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.